QuantRanks is now PatalaRank
Same model. Same universe of roughly 500 stocks. Same monthly ranking. New name under the Patala Portfolio brand.
What if we could read the instruction manual for human life?
This week’s company makes technology that helps scientists do exactly that: read DNA and turn genetic information into data. Its tools support research into cancer, rare diseases, and personalized medicine.
It’s an intriguing business, but an intriguing story isn’t my buy signal.
PatalaRank is. My model ranks roughly 500 stocks each month. This new name earned rank #3.
My SPY market signal remains BUY. So I’m following the system.
How the picks are doing
Ten weeks ago, I began publishing one pick every Sunday and buying at Monday’s open. I personally bought all ten.
10 picks: +4.27% vs. SPY’s −0.77%. Outperformance: +5.03 percentage points ($503.49).
The lead was much larger last week (+19.45% vs. +1.36%). A rough week for my picks, including a 25% drop in LITE in its first week, plus a pullback in SPY, cut it to +4.27% vs. −0.77%. A rules-based strategy doesn’t eliminate volatility, and a strong start doesn’t guarantee future results. I publish the losses alongside the gains.
Subscribe for free to see this week’s new stock, its rank, and the numbers.